BPC 157 Protects Against Clopidogrel-Induced Stomach Damage in Rats

Clopidogrel is a widely prescribed antiplatelet medication used to prevent serious cardiovascular events, but its use is often complicated by significant gastrointestinal side effects, including gastric mucosal injury and peptic ulcers. These adverse effects can lead to patient discomfort, non-compliance, and serious complications like bleeding. Despite existing protective strategies, there remains a need for more effective and targeted interventions to safeguard the stomach lining. This study specifically addresses whether the stable gastric pentadecapeptide BPC 157 can effectively attenuate clopidogrel-induced gastric injury.

The study revealed that clopidogrel administration significantly increased gastric lesion scores and inflammatory markers compared to controls. > Oral administration of BPC 157 profoundly attenuated these adverse effects, leading to a 72% reduction in macroscopic gastric lesion area (from 35.2 ± 4.1 mm² in clopidogrel-alone group to 9.8 ± 2.3 mm² in BPC 157-treated group, p<0.001). Histopathological analysis confirmed a significant decrease in mucosal erosion and inflammatory cell infiltration in the BPC 157-treated group (p<0.01). Furthermore, BPC 157 treatment led to a 55% decrease in pro-inflammatory cytokine TNF-α levels and a 2.3-fold increase in VEGF (vascular endothelial growth factor, a protein promoting blood vessel growth) expression, indicating enhanced healing and angiogenesis. Oxidative stress markers, such as MDA (malondialdehyde), were also reduced by 48% (p<0.001) in the BPC 157 group compared to clopidogrel alone.